Related references
Note: Only part of the references are listed.Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy
Joerg Schilling et al.
BREAST CARE (2022)
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience
Maria Rosaria Valerio et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data
Matti Aapro et al.
ONCOLOGIST (2021)
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study
Luigi Celio et al.
ONCOLOGIST (2021)
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Laurent Zelek et al.
ONCOLOGIST (2021)
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
Lee Schwartzberg et al.
ONCOLOGIST (2020)
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
Roberta Caputo et al.
BMC CANCER (2020)
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo et al.
BONE MARROW TRANSPLANTATION (2020)
Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
Meinolf Karthaus et al.
FUTURE ONCOLOGY (2020)
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
Matti S. Aapro et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
Rudolph M. Navari et al.
Journal of the National Comprehensive Cancer Network (2020)
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting A Randomized Pilot Trial
Rudolph M. Navari et al.
JAMA ONCOLOGY (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy
Eric J. Roeland et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen
Joseph Bubalo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
Giuseppe Badalamenti et al.
SUPPORTIVE CARE IN CANCER (2019)
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey
Pascale Dielenseger et al.
SUPPORTIVE CARE IN CANCER (2019)
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies
Lee Schwartzberg et al.
CANCER MEDICINE (2019)
Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting
Lee S. Schwartzberg et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
Luigi Celio et al.
BMC CANCER (2019)
Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
James Gilmore et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
Rebecca Clark-Snow et al.
SUPPORTIVE CARE IN CANCER (2018)
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
L. Schwartzberg et al.
ANNALS OF ONCOLOGY (2018)
New formulation, new drug? The importance of assessing the safety of new supportive care formulations in oncology
K. Jordan
ANNALS OF ONCOLOGY (2018)
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Amber B. Clemmons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy
Yuka Ito et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study
Michelino De Laurentiis et al.
SUPPORTIVE CARE IN CANCER (2018)
Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey
Matti Aapro et al.
CANCER REPORTS (2018)
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
K. Jordan et al.
ANNALS OF ONCOLOGY (2018)
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
L. Zhang et al.
ANNALS OF ONCOLOGY (2018)
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2017)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen
Eric Roeland et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists
Snezana M. Bosnjak et al.
SUPPORTIVE CARE IN CANCER (2017)
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2017)
Nausea: a review of pathophysiology and therapeutics
Prashant Singh et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K. Jordan et al.
ANNALS OF ONCOLOGY (2015)
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
Cheryl Vidall et al.
SUPPORTIVE CARE IN CANCER (2015)
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari
BIOMED RESEARCH INTERNATIONAL (2015)
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers
Emily S. Van Laar et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
R. J. Gralla et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Thomas Schmitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study
James W. Gilmore et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Preference weights for chemotherapy side effects from the perspective of women with breast cancer
I. Kuchuk et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The Brain Circuitry Underlying the Temporal Evolution of Nausea in Humans
Vitaly Napadow et al.
CEREBRAL CORTEX (2013)
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M. Aapro et al.
ANNALS OF ONCOLOGY (2012)
Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting
Henning Burmeister et al.
SUPPORTIVE CARE IN CANCER (2012)
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life
P. Fernandez-Ortega et al.
SUPPORTIVE CARE IN CANCER (2012)
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art
Steven M. Grunberg et al.
SUPPORTIVE CARE IN CANCER (2011)
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
J Vardy et al.
BRITISH JOURNAL OF CANCER (2006)
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
CC Sun et al.
SUPPORTIVE CARE IN CANCER (2005)
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update
SM Grunberg et al.
SUPPORTIVE CARE IN CANCER (2005)
Share Paper
